INTREXON CORPORATION (NYSE:XON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

As noted in Item5.07 below, at the 2017 Annual Meeting of
Shareholders (the Annual Meeting) of Intrexon Corporation (the
Company), upon recommendation of the Board of Directors of the
Company, the Companys shareholders approved an amendment (the
Amendment) to the Companys Amended and Restated 2013 Omnibus
Incentive Plan, as amended (the Plan), which provides for the
issuance of an additional two million shares of the Companys
common stock under the Plan.

A description of the Amendment is set forth on pages 75 through
77 of the definitive Proxy Statement on Schedule 14A for the 2017
Annual Meeting that was filed with the Securities and Exchange
Commission on May1, 2017, which description is incorporated by
reference herein. The description of the Amendment is qualified
in its entirety by reference to the full text of the Amendment
which is attached as Exhibit 10.1 to this Current Report on Form
8-K and which is incorporated by reference herein.

On June28, 2017, the Company held its 2017 Annual Meeting. At the
2017 Annual Meeting, the Companys shareholders (i)elected each of
the persons listed below as a director for a one-year term,
(ii)ratified the appointment of PricewaterhouseCoopers LLP as the
Companys independent registered accounting firm for the fiscal
year ending December31, 2017, (iii)approved a non-binding
advisory resolution approving the compensation of the named
executive officers, and (iv)approved the Amendment.

Proposal 1 Election of Directors

Proposal 2 Ratification of Appointment of
PricewaterhouseCoopers LLP as the Companys Independent Registered
Public Accounting Firm for the year ended December31, 2017

Proposal 3 Non-binding Advisory Resolution
Approving the Compensation of the Named Executive Officers

Proposal 4 Approval of the Amendment to the
Amended and Restated Intrexon Corporation 2013 Omnibus Incentive
Plan

2

See the Exhibit Index immediately following the page hereto,
which is incorporated herein by reference.

3

INTREXON CORP Exhibit
EX-10.1 2 d419065dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Amendment to the Intrexon Corporation 2013 Omnibus Incentive Plan,…
To view the full exhibit click here
About INTREXON CORPORATION (NYSE:XON)

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.